Immuron (ASX:IMC) partnered with Monash University to develop new therapeutic drug candidates targeting antimicrobial-resistant pathogens, according to a Wednesday filing with the Australian bourse.
The collaboration will involve the Biomedicine Discovery Institute research team and make use of the Immuron technology platform, the filing said.
The parties will negotiate whether to jointly develop or commercialize the outcomes of the research collaboration on commercially reasonable terms after the results are known, per the filing.
Shares fell past 12% in afternoon trade Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.